


We claim:

1. A formulation, comprising: an excipient selected from the group consisting of cyclodextrins, liposomes, micelle forming agents, and polymeric carriers; and a compound represented by **A**:



wherein

m is 0, 1, 2, 3 or 4;

y is 0, 1, or 2;

R₁ represents alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;

R₂ represents H, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;

R₃ represents H, alkyl, aryl, heteroaryl, OR₂, OC(O)R₂, CH₂OR₂, or CO₂R₂;

R₄ represents H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, or heteroaryl;

R₅ represents independently for each occurrence H, alkyl, cycloalkyl, aryl, heteroaryl, F, OR₂, or OC(O)R₂;

R₆ represents independently for each occurrence H, alkyl, cycloalkyl, aryl, heteroaryl, F, OR₂, or OC(O)R₂;

any two geminal or vicinal instances of R₅ and R₆ may be connected through a covalent bond; and

the stereochemical configuration at any stereocenter of a compound represented by **A** is R, S, or a mixture of these configurations.

2. The formulation of claim 1, wherein the excipient is a cyclodextrin.
3. The formulation of claim 1, wherein m is 2 or 3.
4. The formulation of claim 1, wherein m is 2.

5. The formulation of claim 1, wherein y is 0.
6. The formulation of claim 1, wherein R₁ represents aryl or heteroaryl.
7. The formulation of claim 1, wherein R₁ represents aryl.
8. The formulation of claim 1, wherein R₂ represents independently for each occurrence alkyl.
9. The formulation of claim 1, wherein R₃ represents H or alkyl.
10. The formulation of claim 1, wherein R₃ represents H.
11. The formulation of claim 1, wherein R₄ represents cycloalkyl, aryl, or heteroaryl.
12. The formulation of claim 1, wherein R₄ represents aryl.
13. The formulation of claim 1, wherein R₅ represents independently for each occurrence H, or alkyl.
14. The formulation of claim 1, wherein R₅ represents independently for each occurrence H.
15. The formulation of claim 1, wherein R₆ represents independently for each occurrence H, or alkyl.
16. The formulation of claim 1, wherein R₆ represents independently for each occurrence H.
17. The formulation of claim 1, wherein m is 2; and y is 0.
18. The formulation of claim 1, wherein m is 2; y is 0; and R₁ represents aryl.
19. The formulation of claim 1, wherein m is 2; y is 0; and R₁ represents aryl.
20. The formulation of claim 1, wherein m is 2; y is 0; R₁ represents aryl; and R₂ represents independently for each occurrence alkyl.
21. The formulation of claim 1, wherein m is 2; y is 0; R₁ represents aryl; R₂ represents independently for each occurrence alkyl; and R₃ represents H.
22. The formulation of claim 1, wherein m is 2; y is 0; R₁ represents aryl; R₂ represents independently for each occurrence alkyl; R₃ represents H; and R₄ represents

aryl.

23. The formulation of claim 1, wherein m is 2; y is 0; R₁ represents aryl; R₂ represents independently for each occurrence alkyl; R₃ represents H; R₄ represents aryl; and R₅ represents independently for each occurrence H.

24. The formulation of claim 1, wherein m is 2; y is 0; R₁ represents aryl; R₂ represents independently for each occurrence alkyl; R₃ represents H; R₄ represents aryl; R₅ represents independently for each occurrence H; and R₆ represents independently for each occurrence H.

25. The formulation of claim 1, wherein m is 2; y is 0; R₁ represents phenyl; R₂ represents independently for each occurrence ethyl; R₃ represents H; R₄ represents phenyl; R₅ represents independently for each occurrence H; and R₆ represents independently for each occurrence H.

26. A method of treating pain, drug addiction, or tinnitus in a mammal, comprising the step of administering to a mammal in need thereof an effective amount of a formulation of claim 1.

27. The method of claim 26, wherein said mammal is a primate, equine, canine or feline.

28. The method of claim 26, wherein said mammal is a human.

29. The method of claim 26, 27, or 28, wherein said formulation is administered orally.